Evidence map›Paper›PMID 28160034›Full record

ArticlePsychopharmacology2017

The effects of synthetic cannabinoids on executive function.

K Cohen, M Kapitány-Fövény, Y Mama, M Arieli, P Rosca, Z Demetrovics, A Weinstein

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. The Psychonauts' World of Cognitive Enhancers.Frontiers in psychiatry · 2020
    Article
  11. New psychoactive substances: a review and updates.Therapeutic advances in psychopharmacology · 2020
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

K CohenDepartment of Behavioral Science and Integrative Brain and Cognition Center, University of Ariel, Ariel, Israel.
M Kapitány-FövényInstitute of Psychology, Eötvös Loránd University, Budapest, Hungary.
Y MamaDepartment of Behavioral Science and Integrative Brain and Cognition Center, University of Ariel, Ariel, Israel.
M ArieliDivision of Enforcement and Inspection, Ministry of Health, Jerusalem, Israel.
P RoscaDepartment for the Treatment of Substance Abuse, Ministry of Health, Jerusalem, Israel.
Z DemetrovicsInstitute of Psychology, Eötvös Loránd University, Budapest, Hungary.
A WeinsteinDepartment of Behavioral Science and Integrative Brain and Cognition Center, University of Ariel, Ariel, Israel. avivwe@ariel.ac.il.
Eötvös Loránd University · HUAriel University · ILIsrael Ministry of Health · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThere is a growing use of novel psychoactive substances (NPSs) including synthetic cannabinoids. Synthetic cannabinoid products have effects similar to those of natural cannabis but the new synthetic cannabinoids are more potent and dangerous and their use has resulted in various adverse effects. The purpose of the study was to assess whether persistent use of synthetic cannabinoids is associating with impairments of executive function in chronic users.

methodsA total of 38 synthetic cannabinoids users, 43 recreational cannabis users, and 41 non-user subjects were studied in two centers in Hungary and Israel. Computerized cognitive function tests, the classical Stroop word-color task, n-back task, and a free-recall memory task were used.

resultsSynthetic cannabinoid users performed significantly worse than both recreational and non-cannabis users on the n-back task (less accuracy), the Stroop task (overall slow responses and less accuracy), and the long-term memory task (less word recall). Additionally, they have also shown higher ratings of depression and anxiety compared with both recreational and non-users groups. DISCUSSION: This study showed impairment of executive function in synthetic cannabinoid users compared with recreational users of cannabis and non-users. This may have major implications for our understanding of the long-term consequences of synthetic cannabinoid based drugs.

Indexed as

AdultAnxietyCannabinoidsCognitionDepressionExecutive FunctionFemaleHumansMaleMarijuana AbuseMemory, Long-TermMental RecallPsychiatric Status Rating ScalesPsychomotor PerformanceReaction TimeStroop TestCannabinoidsCannabisControl inhibitionLong-term memorySynthetic cannabinoidsWorking memory

Identifiers

PMID28160034
OpenAlexW2585007726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.